TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1501619
Drug: High-Na glucose
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Na glucose electrolyte solution (Na 90 mmol/L)
Study: 1501619
Drug: Low-Na glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Na glucose electrolyte solution (Na 55 mmol/L)
Study: 6371575
Drug: Neurotropic drug
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropic drug (3 X 200 mg EMD 21657)
Study: 30821053
Drug: Evolocumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (both dosing regimens)
Study: 24090993
Drug: Deep massage
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep massage therapy to posterior calf muscles and neural mobilization with self-stretch exercise program (DMS)
Study: 11777715
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium (10 IU/mL) in irrigation solution
Study: 11777715
Drug: Standard irrigating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard irrigating solution without heparin sodium
Study: 11739983
Drug: Aspirin users
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin users (509 patients)
Study: 11739983
Drug: Aspirin users
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin users and Nonusers
Study: 9406835
Drug: Alpha-blocker (terazosin)
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker (terazosin) 2 mg/d for 6 months
Study: 9406835
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 6 months
Study: 9270083
Drug: Alpha-blocker (terazosin)
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker (terazosin)
Study: 8500302
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone or intravenous methylprednisolone followed by oral prednisone
Study: 29705468
Drug: Control CNP
Normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control CNP group (discouraged from using analgesics, allowed paracetamol)
Study: 27717552
Drug: NPC‐01 (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC‐01 (0.02 mg ethinyl estradiol and 1 mg norethisterone)
Study: 25325894
Drug: High aspiration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High aspiration flow rate (40 cc/min; bottle height: 110 cm; vacuum: 400 mm Hg)
Study: 25325894
Drug: Low aspiration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low aspiration flow rate (20 cc/min; bottle height: 90 cm; vacuum: 400 mm Hg)
Study: 20815129
Drug: Medical Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Nutrition Therapy Program (dietary strategies)
Study: 18268073
Drug: Thrice-daily BIAsp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily BIAsp 30
Study: 18268073
Drug: Twice-daily BIAsp
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily BIAsp 30
Study: 10382879
Drug: Moxifloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (200 mg or 400 mg/day for 7 days)
Study: 10382879
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg/day for 7 days)
Study: 1948834
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen therapy (Estraderm)
Study: 18368950
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of cefadroxil (500 mg)
Study: 18368950
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of cefadroxil (500 mg)
Study: 16572062
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (given twice daily during antibiotic therapy)
Study: 12658070
Drug: Naloxone in
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone in combination with Clonidine
Study: 12658070
Drug: Placebo (Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Drug B)
Study: 9108813
Drug: Clomipramine 75-150
Normalized name: clomipramine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 75-150 mg/day
Study: 8475955
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of aspirin from randomization to delivery
Study: 8475955
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment from randomization to delivery
Study: 31433347
Drug: KET/DEX (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KET/DEX (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + 0.7 μg/kg/h infusion of dexmedetomidine for 1.5 hours)
Study: 31433347
Drug: KET/FENT (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KET/FENT (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + three 25 μg fentanyl injections for 1.5 hours)
Study: 15711829
Drug: Cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatment (Interleukin-2 and/or interferon)
Study: 2185340
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus standard therapy followed by maintenance cisplatin for 6 months
Study: 2185340
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin and bleomycin) plus standard therapy
Study: 21034839
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of normal saline injected into the knee joint cavity under ultrasonographic guidance
Study: 21034839
Drug: No joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: No joint infusion (control group)
Study: 17287897
Drug: Famotidine, 20
Normalized name: Famotidine, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 20 mg/day
Study: 17287897
Drug: Rebamipide, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide, 300 mg/day
Study: 10767563
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A - sodium chloride (0.9%) at pH 7.2
Study: 10767563
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B - sodium chloride (0.9%) at pH 5.8
Study: 10767563
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C - Sorensens phosphate buffer (0.06 M) at pH 5.8
Study: 10767563
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D - Sorensens phosphate buffer (0.13 M) at pH 5.8
Study: 10767563
Drug: Formulation E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation E - Sorensens phosphate buffer (0.06 M) adjusted to pH 5.0
Study: 10767563
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (A to E)
Study: 8815751
Drug: Pravastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin + Nicotinic Acid (1.5 g)
Study: 8815751
Drug: Pravastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin + Nicotinic Acid (2.25 to 3 g)
Study: 8815751
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin + Nicotinic Acid)
Study: 27449367
Drug: Triadic parent‐infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triadic parent‐infant Relationship Therapy (TRT)
Study: 21142385
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (antibiotics and percutaneous drainage if necessary, with or without interval appendectomy)
Study: 21142385
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (study group)
Study: 18328195
Drug: Tazarotene 0.1
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1 percent cream plus clindamycin 1 percent gel
Study: 18328195
Drug: Tretinoin 0.025
Normalized name: TRETINOIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025 percent gel plus clindamycin 1 percent gel
Study: 15809121
Drug: Epidural S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural S(+)‐ketamine 0.1 mg/kg
Study: 15809121
Drug: Epidural S(+)‐ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural S(+)‐ketamine 0.1 mg/kg plus epidural clonidine 0.5 microg/kg
Study: 11903080
Drug: Combined femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined femoral and sciatic nerve block with obturator nerve block (5 ml 0.75% ropivacaine)
Study: 11903080
Drug: Combined femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined femoral and sciatic nerve block (15 ml 0.75% ropivacaine to each nerve)
Study: 7727178
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups pooled
Study: 25754396
Drug: Ertugliflozin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 10 mg
Study: 22540407
Drug: Aripiprazole (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (24 mg/day, reduced to 12 mg/day if needed for tolerability)
Study: 23150126
Drug: Red pepper
Normalized name: Red pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red pepper spice (1 g/d)
Study: 23150126
Drug: Turmeric (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (2.8 g/d)
Study: 15519008
Drug: CrCl <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrCl <60 ml/min
Study: 15519008
Drug: CrCl 60
Normalized name: fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CrCl 60 to 89 ml/min
Study: 15519008
Drug: CrCl >89
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrCl >89 ml/min
Study: 11225136
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E capsules 400 units/day
Study: 11225136
Drug: T. arjuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. arjuna tree bark powder 500 mg daily
Study: 7810184
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of digoxin (0.8 mg)
Study: 2112083
Drug: Intravenous portal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous portal chemotherapy for 7 days
Study: 2112083
Drug: Transfused patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfused patients with chemotherapy
Study: 2112083
Drug: Neither transfusions
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither transfusions nor chemotherapy
Study: 333608
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (cephalosporin, 2 gm/day in divided doses for 5 days)
Study: 333608
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (cephalosporin)
Study: 31845139
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg daily during the fasting period after ESD
Study: 24903131
Drug: Nebulised budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised budesonide (800 μg)
Study: 23945072
Drug: Lipegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Study: 23945072
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Study: 21773781
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (rFSH) with starting dose of 75-100 IU daily
Study: 21773781
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) at 100 mg/day for 5 days
Study: 19341123
Drug: Hyperbaric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric treatment group (33 patients)
Study: 10047639
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 to 60 mg/day)
Study: 10047639
Drug: Azosemide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azosemide (60 to 90 mg/day)
Study: 7762839
Drug: Ketorolac (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (0.9 mg/kg)
Study: 7762839
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (2 mL)
Study: 7000260
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injections of insulin (Monotard plus Actrapid)
Study: 7000260
Drug: Twice-daily injections
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily injections of insulin (Semitard plus Actrapid)
Study: 11974458
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy for palliation by ablation, dilatation, or stenting
Study: 11974458
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment of postoperative complications
Study: 11974458
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment of anastomotic strictures
Study: 30252113
Drug: No interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: No interview (treatment-as-usual control)
Study: 17512015
Drug: N2O and
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O and oxygen inhalation (group 1)
Study: 16240961
Drug: Prompt L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt L‐Pop (PLP)
Study: 11906359
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous birch pollen immunotherapy (IT)
Study: 10434231
Drug: Valganciclovir 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 360 mg
Study: 10434231
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1000 mg
Study: 10434231
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir 5 mg/kg
Study: 2140848
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading with L-tryptophan
Study: 2140848
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant treatment
Study: 25456867
Drug: Prolastin C
Normalized name: PROLASTIN C 1000mg Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin C (human plasma-derived AAT) at 60 mg/kg infused intravenously within 12 hours of admission
Study: 21853425
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (group A)
Study: 21853425
Drug: Fluconazole nasal
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole nasal spray (group B)
Study: 21853425
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral itraconazole and nasal fluconazole (group C)
Study: 21853425
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with fluconazole solution (group D)
Study: 21853425
Drug: Convenient medical
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convenient medical treatment only (group E)
Study: 19663129
Drug: Budesonide/formoterol pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI, 80/4.5 microg (320/18 microg/d) twice daily
Study: 19663129
Drug: Budesonide/formoterol pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI, 160/4.5 microg (320/9 microg/d) once daily
Study: 19663129
Drug: Budesonide/formoterol pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI, 80/4.5 microg (160/9 microg/d) once daily
Study: 19663129
Drug: Budesonide pMDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide pMDI, 160 microg (320 microg/d) once daily
Study: 16323085
Drug: Famciclovir (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (1000 mg given twice daily)
Study: 1824707
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-estradiol (Estraderm; 0, 50, 100, or 150 micrograms/day) combined with oral medroxyprogesterone acetate (10 mg each day) during weeks 3-4 and 7-8 of each 8-week regimen
Study: 28746186
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone for patients with PIV >=8
Study: 19405936
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with concurrent chemotherapy (docetaxel)
Study: 16922703
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily amount of red wine
Study: 11471853
Drug: Zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (10 mg/day)
Study: 11471853
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg/day)
Study: 8291963
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (high doses > 1,000 micrograms/d)
Study: 3174151
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 5 mg in 5 ml of saline
Study: 31516025
Drug: Unencapsulated formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unencapsulated formulations
Study: 29420164
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg per day)
Study: 22927165
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg taken four times a day for 1 week)
Study: 22927165
Drug: No ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No ibuprofen
Study: 21626222
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) at an initial dose of 5 mg/kg for 12 months
Study: 21626222
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 3 pulses of 30 mg/kg followed by prednisone for 4 months
Study: 21626222
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (identical treatment without randomization)
Study: 10783653
Drug: Inhaled NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NO
Study: 10430735
Drug: Intravenous PGI(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PGI(2)
Study: 10783653
Drug: Systemic calcium
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic calcium antagonists (CAAs)
Study: 10783653
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with aerosolized iloprost
Study: 7582384
Drug: Dispersible diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible diclofenac (100 mg)
Study: 7582384
Drug: Enteric-coated diclofenac
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric-coated diclofenac (100 mg)
Study: 399090
Drug: Synalar cream
Normalized name: Synalar Cream
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synalar cream (fluocinolone acetonide 0.025%)
Study: 399090
Drug: Cortoderm ointment
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortoderm ointment (fluocinolone acetonide 0.025%)
Study: 31140297
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg/day for 1 year after trastuzumab-based adjuvant therapy
Study: 31140297
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 1 year after trastuzumab-based adjuvant therapy
Study: 30305078
Drug: Integrated motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated motivational interviewing and cognitive behaviour therapy (MI-CBT)
Study: 30238433
Drug: Riociguat 2
Normalized name: riociguat 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 2 mg
Study: 21139557
Drug: Topical corticotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks + emollient cream applied twice a day for 4 weeks
Study: 21139557
Drug: Topical corticotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks
Study: 15654072
Drug: Premenopausal women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premenopausal women taking a combined monophasic oral contraceptive
Study: 10416734
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g anhydrous dextrose plus 4 mg sodium saccharin